References:
Glucerna is a Food for Special Medical Purposes. Use under medical supervision.
1. Therapeutic Goods Administration (2025) Liraglutide- medicine shortage information. TGA Medicines shortage reports database. Available at: https://apps.tga.gov.au/shortages/search/Details/liraglutide (Accessed: 13 October 2025).
2. Htike, ZZ. et al. (2017). Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab, 19(4), pp. 524-536.
3. Moiz, A. et al. (2025). Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: A systematic review of randomized controlled trials. Ann Intern Med, 178(2), pp. 199-217.
4. Ussher, J.R. and Drucker, D.J. (2023). Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol, 20, pp. 463-474.
5. Liotta, M. (2025) Examining the pros and cons of semaglutide, RACGP newsGP, 21 January. Available at: https://www1.racgp.org.au/newsgp/clinical/examining-the-pros-and-cons-of-semaglutide (Accessed: 13 October 2025).
6. Moiz, A. et al. (2025). Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation. Am J Med, 138(6): pp. 934-940.
7. BMJ (2025). Side effects of GLP-1 receptor agonists. BMJ, 390, r1606.
8. Tobaiqy, M. (2024) A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment. Pharmacological Reports, 76, pp. 981–990.
9. Glucerna® Powder Product Label.
10. Mottalib, A. et al. (2016). Impact of diabetes-specific nutritional formulas versus oatmeal on postprandial glucose, insulin, GLP-1 and postprandial lipidemia. Nutrients, 8(7), pp 443.
11. Thomas, S., Besecker, B., Choe, Y. and Christofides, E. (2024) Postprandial glycemic response to a high-protein diabetes-specific nutritional shake compared to isocaloric instant oatmeal in people with type 2 diabetes: a randomized, controlled, crossover trial. Front Clin Diabetes Healthc. 5: 1399410.
12. Tey, S, L. et al. (2024). Diabetes-specific formula with standard of care improves glycemic control, body composition, and cardiometabolic risk factors in overweight and obese adults with type 2 diabetes: results from a randomized controlled trial. Front Nutr. 11: 1400580.
13. Lin, S.S., Stuk, S., Jackson, H., Deed, G., Ross, G.P. and Andrikopoulos, S. (2024) Consensus Statement: The Use of Diabetes Specific Nutritional Formulas in Type 2 Diabetes. Australian Diabetes Society, Australian Diabetes Educators Association, Royal Australian College of General Practitioners, and Dietitians Australia.
14. Peng J et al. Br J Nutr 2019;121:560–66.
15. Bevilacqua A, et al. Int J Endocrinol. 2018;2018:1968450.
16. Dang NT, et al. Biosci Biotechnol Biochem. 2010;74(5):1062–67.
17. Yamashita Y, et al. J Agric Food Chem. 2013;61(20):4850-54.
* When taken as a breakfast replacement as part of a diabetes management plan, people with diabetes consuming Glucerna kept blood sugar within the target glucose range of 3.9 - 10.0 mmol/L for an average of 89.5% of the time.
ANZ.2025.68113.GLU.1 (v1.0)